Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript

August 3, 2026 4:30 PM EDT

Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO, President & Director Duncan J. McKechnie - Chief Commercial Officer, Head of North America Commercial & Executive VP Charles Wagner - Executive VP, COO & CFO

Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Cory Kasimov - Evercore ISI Institutional Equities, Research Division Brian Abrahams - RBC Capital Markets, Research Division Evan Seigerman - BMO Capital Markets Equity Research Michael Yee - UBS Investment Bank, Research Division Tazeen Ahmad - BofA Securities, Research Division Philip Nadeau - TD Cowen, Research Division Terence Flynn - Morgan Stanley, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Eliana Merle - Barclays Bank PLC, Research Division

Presentation Operator Good day, and welcome to the Vertex Pharmaceuticals Second Quarter 2026 Earnings Call.

Susie Lisa Senior Vice President of Investor Relations Good evening, all. My name is Susie Lisa, and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to our Second Quarter 2026 Financial Results Conference Call. On tonight's call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and President; Charlie Wagner, Chief Operating Officer and Chief Financial Officer; and Duncan McKechnie, Chief Commercial Officer. We recommend that you access the webcast slides as you listen to this call. The call is being recorded, and a replay will be available on our website. We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail